Chemical & Engineering News, 89(7), February 14, 2011
“At Bicoll Biotechnology in Shanghai’s Zhangjiang Hi-Tech Park, Managing Director Kai Lamottke is skeptical that the Chinese drug industry has openings for a sizable contingent of scientists from abroad. “The scientists with foreign experience represent, in percentage terms, a tiny minority of employees in the Chinese pharmaceutical sector,” he says. “Besides, I doubt that you can make things more productive only by the infusion of foreign talent.”
Read more in C&EN
